PPD Strengthens Global Risk Management Services with Appointment of REMS Expert

23 Mar. 2010


WILMINGTON, N.C. (March 23, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced it has named Frank Gallo as executive director of risk management, strengthening its expertise in risk evaluation and mitigation strategies (REMS). Mr. Gallo will lead the development, management and implementation of REMS programs that align with client program goals and product commercialization.

Mr. Gallo brings more than 13 years of pharmaceutical, commercial and risk management experience to PPD's risk management teams in epidemiology, late stage surveillance studies, pregnancy registries, pharmacovigilance and medical communications. He previously served as vice president of Rienzi & Rienzi, a healthcare communications company, where he developed and designed REMS communications strategies and programs for U.S. Food and Drug Administration (FDA) approval. Mr. Gallo's expertise includes risk management and commercial positions with Talecris Biotherapeutics and Mylan Inc.

"The safety of marketed drugs remains an important concern for our clients and regulatory authorities," said Lori Eberhardt, vice president of global late stage research for PPD. "Frank brings strong expertise across a range of risk management programs and therapies, which will benefit our clients in developing REMS strategies for drugs or biologics that offer significant benefits but may also involve health or safety risks."

Mr. Gallo earned his bachelor of science from West Virginia University and is a member of the Drug Information Association (DIA) and the Scientific Board for National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™).

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the above named employee's performance and growth of our late stage research services business, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; competition within the outsourcing industry; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; rapid technological advances that make our products and services less competitive; success in sales growth; loss of large contracts; increased cancellation rates; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
Tel: +1 919 456 4425

Holly Devine Manager, Corporate Communications
Tel: +1 919 456 6389

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2019 Pharmaceutical Product Development, LLC. All rights reserved.